Alzheimer's Assocation Research only
All of alz.org
  • Go to Alz.org
  • Research Center
  • AAIC
  • ISTAART
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Home
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Types of Research Grants


Grants Overview Types of Grants Process and Timeline Funded Studies

The Alzheimer's Association funds a wide variety of investigations by scientists at every stage of their careers. Each grant is designed to meet the needs of the field and to introduce fresh ideas in Alzheimer's research.




2018 International Research Grant Program - June Program (February - August 2018)


Alzheimer's Association Research Grant (AARG)

The Alzheimer's Association Research Grant aims to fund investigators who are less than 10 years past their doctoral or post residency (MD or DO). The purpose of this program is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The Alzheimer's Association recognizes the need to increase the number of scientists from underrepresented groups in the research enterprise. Young scientists from these groups are encouraged to apply. Applicants must be Assistant Professors or above at their respective institution.



Alzheimer's Association Research Grant to Promote Diversity (AARG-D)

The Alzheimer's Association Research Grant to Promote Diversity program award is up to three years (minimum 2 years) to increase the number of scientist from underrepresented groups at academic institutions in Alzheimer's or related dementias research. The AARG-D aims to fund investigators who are less than 10 years past their doctoral or post residency (MD or DO). The objective of this award is to increase the number of highly trained investigators from diverse backgrounds whose basic, clinical and social/behavioral research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to Alzheimer's and related dementias in general and in health disparities populations. The Alzheimer's Association recognizes the need to increase the number of scientist from underrepresented groups participating in biomedical and behavioral research. The Association anticipates that by providing these research opportunities, the number of scientist from underrepresented groups entering and remaining in biomedical research careers in Alzheimer's disease will increase.



Alzheimer's Association Research Grant — New to the Field (AARG-NTF)

The Alzheimer's Association Research Grant — New to the Field (AARG-NTF) aims to fund investigators who are over the 10 years since last terminal degree and are new to Alzheimer's and related dementia field of research. Individuals who are over 10 years since last terminal degree and new to the field of neuroscience or neurodegeneration (Alzheimer's, Parkinson's, Lewy body dementia, etc) will be considered for this program. If you are still within 10 years since last terminal degree you must apply to the regular AARG program.



Alzheimer's Association Research Grant to Promote Diversity — New to the Field (AARG-D-NTF)

The Alzheimer's Association Research Grant to Promote Diversity- New to the Field program award is up to three years (minimum 2 years) to increase the number of scientist from underrepresented groups at academic institutions in Alzheimer's or related dementias research. The AARG-D-NTF aims to fund individuals over the 10 years since last terminal degree and are new to Alzheimer's and related dementia field of research. Individuals who are over 10 years since last terminal degree and new to the field of neuroscience or neurodegeneration (Alzheimer's, Parkinson's, Lewy body dementia, etc) will be considered for this program. If you are still within 10 years since last terminal degree you must apply to the regular AARG program.



Alzheimer's Association Research Fellowship (AARF)

The Alzheimer's Association Research Fellowship Award Program is a three year (minimum 2 year) award intended to support exceptional researchers who are engaged in their post-graduate work (i.e. postdoctoral fellows) and before they have their first independent faculty positions (i.e. Assistant Professor) with the goal of bridging the fellow to faculty positions of researchers. Please note, individuals applying to the program will be accepted from postdoctoral fellows with full time positions at their respective institution who have less than 10 years of research experience after receipt of their doctorate or other terminal degree. Individuals who have a position of an Assistant Professorship or above are not eligible.



Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D)

The Alzheimer's Association Research Fellowship Award to Promote Diversity Program is a three year (minimum 2 year) award intended to support exceptional researchers who are currently underrepresented at academic institutions in Alzheimer's or related dementias research and who are engaged in their post-graduate work (i.e. postdoctoral fellows) and before they have their first independent faculty positions (i.e. Assistant Professor) with the goal of bridging fellow to faculty position of researchers. Please note, individuals applying to the program will be accepted from postdoctoral fellows with full time positions at their respective institution who have less than 10 years of research experience after receipt of their doctorate or other terminal degree. Individuals who have a position of an Assistant Professorship or above are not eligible.



Alzheimer's Association Clinician Scientist Fellowship (AACSF)

The Alzheimer's Association recognizes the need to support the training of clinician scientists in Alzheimer's and related dementias. For the purpose of this program, a clinician scientist is defined as an individual already trained, licensed and practicing in a clinical field that includes patient contact (e.g., neurology, psychiatry, geriatrics, psychology) or patient-related diagnostic studies (e.g.,neuropathology and radiology). Applicants who hold an M.D. or D.O. degree or applicants with a Ph.D. who have licensure for clinical practice are eligible. Please note, individuals applying to the program will be accepted from individuals with full time positions at their respective institution who are within 10 years of receiving their M.D., D.O. or Ph.D. (or equivalent), including postdoctoral fellows through Assistant Professors. Positions higher than Assistant Professor will not be considered.

Please note individuals must be currently in a clinical setting.



Alzheimer's Association Clinician Scientist Fellowship to Promote Diversity (AACSF-D)

The Alzheimer's Association Clinician Scientist Fellowship to Promote Diversity is up to three years (minimum 2 years) and is intended to support exceptional clinician scientist who are currently underrepresented at academic institutions in clinical research training in Alzheimer's and related dementias. Applicants who hold an M.D. or D.O. degree or applicants with a Ph.D. who have licensure for clinical practice are eligible. For the purpose of this fellowship, clinical research is defined as patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research." Disease related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases. The Alzheimer's Association recognizes the need to increase the number of underrepresented clinicians participating in clinical research. The Association anticipates that by providing this funding opportunity, the number of underrepresented physicians entering and remaining in clinical careers in Alzheimer's disease will increase. Please note, individuals applying to the program will be accepted from individuals with full time positions at their respective institution who are within 10 years of receiving their M.D., D.O. or Ph.D. (or equivalent), including postdoctoral fellows through Assistant Professors. Positions higher than Assistant Professor will not be considered.

Please note individuals must be currently in a clinical setting.



The Zenith Fellows Award Program (Zenith)

The Zenith Fellows award was initiated in 1991 to provide a vehicle for research support for donors with a substantial personal commitment to the advancement of Alzheimer's disease research. The awards are made possible by the generosity of a group of individuals and organizations (Zenith Society) that have each committed $1 million to the Alzheimer's Association for support of the program.

The objective of the 2018 Zenith Fellows Awards competition is to provide major support for investigators who have:

  • Contributed significantly to the field of Alzheimer's disease research,
  • Made significant contributions to other areas of science and are now beginning to focus more directly on problems related to Alzheimer's disease, and
  • Are likely to make substantial contributions in the future.

The proposed research must be "on the cutting edge" of basic science or biomedical research and thus may not conform to current conventional scientific wisdom or may challenge the prevailing orthodoxy. The proposed research should address fundamental problems related to early detection, etiology, pathogenesis, treatment and/or prevention of Alzheimer's disease.



The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease

The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease program will accelerate the discovery and testing of innovative compounds to be used for interventions in the earliest stages of neurodegeneration-dementia-Alzheimer's disease.

Applications for the PTC program will be accepted that include lead candidate therapeutic agents targeting neuronal growth factors, cell survival and cell cycle pathways, anti-apoptotic or anti-cell death mechanisms and related mechanisms. These targets should be at a stage that require early stage phase 1 testing prior to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) phase 2 study in preparation for larger-scale POC trials. Awards should be able to demonstrate significant advancement of the compound within two years (24 months) of the award. Funding will support Phase 1 or early Phase 2 studies (Phase 2a, including proof of concept, proof of mechanism) of new or repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer's disease (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. Any proposal must have a clear relevance to Alzheimer's disease and be translational in nature. While preliminary preclinical animal studies can be a component of the larger proposal and as a part of the study design, proposals must include human clinical trials for eligibility. Proposals should include a plan for how participants are being selected, for instance confirming that there are already Alzheimer's disease related changes or neuronal or other cell death pathology in the individual; this can include fluid, imaging or other biological measures. All proposals should clearly and explicitly outline the type of study, the rationale for the study, the participant selection process, the methods for study, and outcomes. This can include use of appropriate biomarker measures (fluid, imaging or other) to identify participants and/or to confirm target engagement throughout the study as well, as applicable.

Both non-profit and for-profit agencies from the international scientific community are eligible. Small for-profit agencies must submit documentation of net assets and annual earnings for consideration during the letter of intent process. Not-for-profit organizations must submit documentation verifying status during the letter of intent process. Researchers with full-time staff or faculty appointments are encouraged to apply. Applications from post-doctoral candidates will not be accepted. For questions as to whether an investigator or organization is eligible, please contact the Alzheimer's Association at grantsapp@alz.org.

Letters of Intent (LOI) must be received by 5:00 PM ET, March 5, 2018.

Made possible through the generous funding of The Part the Cloud, benefiting the Alzheimer's Association

 



CLOSED: The Tau Pipeline Enabling Program (T-PEP)

Full program details can be found at alz.org/T-PEP.




By Invitation for Atlantic Fellows Only

Pilot Awards for Global Brain Health Leaders

The Global Brain Health Institute (GBHI) and the Alzheimer's Association aim to support emerging leaders in brain health and dementia by funding small-scale pilot projects and/or studies (hereafter referred to as "pilot project(s)") to advance skills, knowledge, activities and general efforts to delay, prevent and/or mitigate the impact of dementia. The goal of these awards is to both support leadership development of the awardee and to advance the pilot projects that improve outcomes in brain health and dementia.

The Global Brain Health Institute (GBHI) trains a new generation of health leaders empowered to break down disciplinary boundaries and to find innovative ways to intervene on behalf of vulnerable people in their communities to prevent and limit the impact of dementia globally. GBHI brings together two leading institutions in brain science, the University of California, San Francisco (UCSF) and Trinity College Dublin, the University of Dublin (TCD). As the world's leading non-profit funder of Alzheimer's and dementia related research, the Alzheimer's Association shares the commitment to developing the next generation of brain health leaders, aligning with the vision and mission of GBHI. To further emphasize the commitment to these goals, GBHI and the Alzheimer's Association are partnering to offer the Pilot Awards for Global Brain Health Leaders for Atlantic Fellows for Equity in Brain Health at GBHI.

For more information on the pilot program, contact grantsapp@alz.org and pilots.projects@gbhi.org. For more information on the Global Brain Health Institute (GBHI), please visit gbhi.org or contact info@gbhi.org.

 


 

 

 

For more information: Contact grantsapp@alz.org or call 312.335.5747.